Why Is GALERA THERAPEUTICS (OBX) Stock Up Today?

Why OBX stock is up today

Obsidian Therapeutics Inc stock surged by 30.00% to $35.90 in a volatile session driven by a merger-related corporate action and renewed market interest. The stock opened with a 3.6% gap up from the prior close and reached a session high of $37.15 before settling at $35.90. The move coincided with the resumption of trading following a volatility trading pause and the initiation of coverage by Piper Sandler with an Overweight rating and a $42 price target.

What Happened

Obsidian Therapeutics announced a merger at $0 per share with a conversion ratio of 0.7019-for-1, which triggered a trading halt and subsequent volatility trading pause. Trading resumed with a significant upward move as the stock opened at $28.50 and climbed steadily throughout the session. The company also reported the enrollment of its first participant in the Phase 1/2 Agni-01 trial for amsokigene autoleucel, a treatment for advanced or metastatic melanoma. This development, along with the initiation of coverage by Piper Sandler, added to the momentum.

What The Data Shows

The stock traded at 0.0M shares so far in the session, which is 9.2 times the 3-month daily average. The intraday high of $37.15 occurred at 11:05 AM ET, while the low of $28.50 was recorded at 10:50 AM ET. Obsidian Therapeutics has a market cap of $1.2B, with an unprofitable earnings profile (TTM EPS -1287.13) and a beta of 2.61. The stock is currently trading within its 52-week range of $23.00 to $49.97.

What To Watch

The stock is currently under new coverage from Piper Sandler, which may influence its near-term performance. Investors should monitor the progress of the Agni-01 trial and any further developments from the merger process.